Sanofi is back with its second…
Sanofi is back with its second pact of the day, [...]
MapLight Therapeutics is the…
MapLight Therapeutics is the latest biotech to want a turn [...]
Aviceda Therapeutics has hit a…
Aviceda Therapeutics has hit a snag in its goal to [...]
Fresh off a $153 million series E…
Fresh off a $153 million series E round, Arthrosi Therapeutics [...]
After a year marked by dramatic…
After a year marked by dramatic ups and downs, William [...]
Zealand Pharma may be gearing up…
Zealand Pharma may be gearing up for a high-stakes year [...]
A key late-stage trial of Arcus…
A key late-stage trial of Arcus Biosciences and Gilead’s anti-TIGIT [...]
Cycle Pharmaceuticals is circling…
Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare [...]
Rezolute’s stock has plunged 87%…
Rezolute’s stock has plunged 87% after the company’s rare disease [...]
Eli Lilly has surpassed…
Eli Lilly has surpassed analysts’ highest hopes for the efficacy [...]